Eli Lilly and Company (NYSE:LLY) Trading Down 3.6% - Time to Sell?

Key Points

• Shares fell 3.6% on Friday to about $885 with volume up ~43%, largely driven by investor concern after mixed weekly GLP‑1 prescription data and weak early uptake of Foundayo (~3,707 US prescriptions in week two vs ~18,410 for oral Wegovy).
• Analysts remain broadly positive — the consensus rating is "Moderate Buy" with a consensus target around $1,225, and several firms have raised targets into the $1,200–$1,350 range.
• Company fundamentals and guidance are strong: last quarter beat EPS expectations ($7.54) with revenue up ~42.6% year‑over‑year, and management set FY2026 guidance of 33.5–35.0 EPS.

Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) dropped 3.6% on Friday . The company traded as low as $871.73 and last traded at $884.8750. Approximately 4,447,698 shares were traded during trading, an increase of 43% from the average daily volume of 3,121,033 shares. The stock had previously closed at $917.65.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst upgrade and higher price target lifted sentiment earlier in the session — a firm raised LLY’s price target to $1,183 and another note drove a brief bounce. Price Target Raised to $1,183
• Positive Sentiment: Expanded Hims & Hers partnership increases distribution pathways for Lilly’s GLP‑1s (including Zepbound) via the LillyDirect fill platform, supporting commercial reach. LLY Expands Partnership with Hims & Hers
• Positive Sentiment: Early-stage development risk eased after completion of the Phase 1 renal study for LY3537982, lowering a pipeline overhang. LY3537982 Renal Study Reaches Completion
• Neutral Sentiment: Broader strategic moves and M&A mentions (reporting Lilly’s acquisition of Kelonia for ~$7B) are noteworthy for long‑term positioning but are secondary to near‑term commercial signals. Deal Dispatch: Major M&A (includes Kelonia)
• Neutral Sentiment: Upcoming Q1 earnings (April 30) increase sensitivity — mixed weekly prescription trends make the stock more volatile ahead of the report. Weekly GLP-1 Data and Earnings Sensitivity
• Negative Sentiment: Foundayo early uptake trailed expectations — IQVIA data showed ~3,707 US prescriptions in week two (vs. oral Wegovy’s ~18,410 benchmark), prompting investor concern about obesity market share and near‑term demand. Foundayo Trails Wegovy in Early Uptake
• Negative Sentiment: Weekly GLP‑1 prescription trackers showed mixed trends that investors interpret as a near‑term demand risk for a stock priced for strong execution; that dynamic appears to be the main driver of today’s weakness. Reuters: Foundayo Prescriptions ~3,707 in Week Two

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. Freedom Capital upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, February 10th. Barclays initiated coverage on Eli Lilly and Company in a research report on Thursday, February 19th. They set an "overweight" rating and a $1,350.00 target price for the company. Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a research report on Tuesday, February 10th. Berenberg Bank boosted their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a "hold" rating in a research report on Thursday, February 19th. Finally, Daiwa Securities Group lifted their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a "buy" rating in a research note on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,225.33.

Eli Lilly and Company Trading Down 3.6%

The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The business has a 50 day moving average of $961.94 and a 200 day moving average of $983.63. The firm has a market capitalization of $836.05 billion, a price-to-earnings ratio of 38.56, a PEG ratio of 1.09 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts' consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. During the same period in the previous year, the firm earned $5.32 earnings per share. The firm's quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 33.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. 10Elms LLP boosted its position in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after buying an additional 10 shares during the period. M.E. Allison & CO. Inc. boosted its position in shares of Eli Lilly and Company by 0.7% during the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company's stock worth $1,587,000 after buying an additional 10 shares during the period. Tanager Wealth Management LLP boosted its position in shares of Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock worth $424,000 after buying an additional 10 shares during the period. Morey & Quinn Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 1.5% during the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock worth $710,000 after buying an additional 10 shares during the period. Finally, Wealthspan Partners LLC boosted its position in shares of Eli Lilly and Company by 0.5% during the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock worth $2,268,000 after buying an additional 10 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.